Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph
FDA proposes to revise regulations on fixed-combination and co-packaged drugs, which may affect cosmetics that are also considered drugs (e.g., anti-dandruff shampoos, sunscreens). This is a proposed rule from 2015, not a final action, but indicates potential future changes in combination product oversight.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Indie beauty brands, contract manufacturers, private-label makers, importers/distributors that produce or market cosmetics with drug claims (e.g., anti-acne, sun protection, antiperspirant). should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; final rule not yet issued.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA is proposing to clarify and update approval pathways for fixed-combination and co-packaged drugs, which could impact how combination cosmetic-drug products are regulated.
Who it affects
Indie beauty brands, contract manufacturers, private-label makers, importers/distributors that produce or market cosmetics with drug claims (e.g., anti-acne, sun protection, antiperspirant).
What you must do
Monitor FDA for final rule; review current product classifications to ensure compliance with drug regulations if applicable.
Deadline
No immediate deadline; final rule not yet issued.
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection